327 related articles for article (PubMed ID: 28142309)
1. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
2. Five-year experience of organized colorectal cancer screening in a Swedish population - increased compliance with age, female gender, and subsequent screening round.
Blom J; Kilpeläinen S; Hultcrantz R; Törnberg S
J Med Screen; 2014 Sep; 21(3):144-50. PubMed ID: 25070434
[TBL] [Abstract][Full Text] [Related]
3. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
4. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
5. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
Mlakar DN; Bric TK; Škrjanec AL; Krajc M
Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
[TBL] [Abstract][Full Text] [Related]
6. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.
Wong BC; Wong WM; Cheung KL; Tong TS; Rozen P; Young GP; Chu KW; Ho J; Law WL; Tung HM; Lai KC; Hu WH; Chan CK; Lam SK
Aliment Pharmacol Ther; 2003 Nov; 18(9):941-6. PubMed ID: 14616158
[TBL] [Abstract][Full Text] [Related]
7. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
8. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
[TBL] [Abstract][Full Text] [Related]
9. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
10. Initial participation as a predictor for continuous participation in population-based colorectal cancer screening.
Saraste D; Öhman DJ; Sventelius M; Elfström KM; Blom J; Törnberg S
J Med Screen; 2018 Sep; 25(3):126-133. PubMed ID: 28786766
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
12. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
Brenner H; Tao S
Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
[TBL] [Abstract][Full Text] [Related]
13. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
[No Abstract] [Full Text] [Related]
14. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
[TBL] [Abstract][Full Text] [Related]
15. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
[TBL] [Abstract][Full Text] [Related]
16. Men with negative results of guaiac-based fecal occult blood test have higher prevalences of colorectal neoplasms than women with positive results.
Brenner H; Hoffmeister M; Birkner B; Stock C
Int J Cancer; 2014 Jun; 134(12):2927-34. PubMed ID: 24374771
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching.
Leuraud K; Jezewski-Serra D; Viguier J; Salines E
Cancer Epidemiol; 2013 Dec; 37(6):959-67. PubMed ID: 24035240
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
[TBL] [Abstract][Full Text] [Related]
19. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]